Janssen v. Apotex: Appeal Dismissed, CA2655335C Upheld for INVEGA SUSTENNA
The Federal Court of Appeal dismissed Apotex’s appeal in Case A-36-22, affirming the lower court’s declaratory judgment in favour of Janssen and its patent CA2655335C covering INVEGA SUSTENNA. The appellate court found no palpable and overriding error in the Federal Court’s factual findings, awarding Janssen $10,000 in agreed costs.
Appellate affirmation of Janssen’s INVEGA SUSTENNA patent in Canadian PM/NOC proceedings
Case A-36-22 is an appeal before the Federal Court of Appeal of Canada, brought by Apotex Inc. against a declaratory judgment issued by the Federal Court in favour of Janssen Inc. The dispute centres on Canadian patent CA2655335C, which covers INVEGA SUSTENNA — Janssen’s long-acting injectable formulation of paliperidone palmitate used in the treatment of schizophrenia. The case arises in the context of Canada’s Patented Medicines (Notice of Compliance) Regulations, under which Janssen sought judicial protection against Apotex’s proposed generic entry.
The Federal Court of Appeal closed the matter on 12 January 2024, dismissing Apotex’s appeal in full and awarding costs to Janssen in the agreed all-inclusive amount of $10,000. The appellate court applied the deferential ‘palpable and overriding error’ standard to the Federal Court’s factual findings, concluding that the lower court had not erred in law and was entitled to draw inferences from the evidence that Apotex’s product monograph would give rise to the required influence — the key legal threshold in an inducement-of-infringement analysis.
The swift appellate resolution, with costs pre-agreed between the parties, suggests a degree of litigation management discipline and may indicate that the appeal was a tactical step rather than a high-stakes reversal attempt. The public record does not disclose the full factual record underlying the Federal Court’s original finding, nor the specific claims of CA2655335C most directly in dispute. What is clear is that the appellate court’s endorsement of the lower court’s reasoning strengthens Janssen’s regulatory and exclusivity position for INVEGA SUSTENNA in the Canadian market.
Filing to dismissal in 0 days
Closed 12 January 2024 — appellate decision on Federal Court declaratory judgment
Federal Court of Appeal dismisses Apotex’s appeal, affirming Janssen’s patent position
Palpable and overriding error: a high bar Apotex could not clear
Canadian appellate courts reviewing factual findings apply the ‘palpable and overriding error’ standard — one of the most deferential in Canadian civil procedure. Apotex was required to show not merely that the Federal Court could have decided differently, but that it made an obvious, determinative mistake. The Court of Appeal found no such error, meaning the lower court’s inferences from the evidence stood unrevisited.
Highly deferential review standardInducement of infringement: why Apotex’s product monograph was decisive
The Federal Court’s original finding turned on whether Apotex’s product monograph would give rise to the ‘required influence’ — a reference to the inducement-of-infringement test under Canadian patent law, which asks whether a party directs or procures another to infringe. Product monographs in pharmaceutical NOC proceedings frequently become battlegrounds because prescribing guidance can function as the infringing act’s catalyst. The appellate court accepted that the evidence supported this threshold being met.
Inducement threshold confirmedPM/NOC framework: how this case fits Canada’s generic entry regime
Canada’s Patented Medicines (Notice of Compliance) Regulations create a linkage regime between patent protection and generic marketing approval. A successful declaratory judgment by Janssen under this framework can delay or prevent Apotex from obtaining its NOC for a generic paliperidone palmitate product. The appellate dismissal reinforces the regulatory barrier, preserving INVEGA SUSTENNA’s market position for the duration of CA2655335C’s remaining term.
NOC regulatory barrier maintainedPre-agreed costs signal litigation pragmatism from both parties
The $10,000 all-inclusive agreed costs award is modest by pharmaceutical patent litigation standards. Pre-agreed cost figures typically indicate that both parties negotiated the quantum in advance, consistent with a cooperative litigation management approach. This suggests the appeal may have been pursued primarily to preserve appellate rights or for strategic positioning, rather than as a high-conviction attempt to overturn the Federal Court’s findings.
Costs pre-agreed — $10,000Full party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Plaintiff | Company | Pharmaceutical innovator — holder of CA2655335C covering INVEGA SUSTENNA paliperidone palmitateSearch in Eureka ↗ |
| Defendant | Defendant | Company | Canadian generic pharmaceutical manufacturer seeking NOC for paliperidone palmitate productSearch in Eureka ↗ |
| Presiding judge | Judge / | Chief Judge | Canada Federal Court of Appeal — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The appellate court’s language is precise and deliberately deferential. By framing the infringement threshold as ‘a factually suffused issue’ and invoking the palpable and overriding error standard, the court signals that it would not substitute its own view of the evidence. The phrase ‘was entitled to draw inferences’ is significant — it confirms the Federal Court had evidential latitude, not merely legal discretion. For Janssen, this is a durable win; for Apotex, the door to further Canadian challenge on this patent appears effectively closed at the appellate level.
CA2655335C — INVEGA SUSTENNA long-acting injectable paliperidone palmitate
Canadian patent CA2655335C protects technology underlying INVEGA SUSTENNA, Janssen’s once-monthly long-acting injectable formulation of paliperidone palmitate — an atypical antipsychotic approved for schizophrenia and schizoaffective disorder. Long-acting injectables (LAIs) represent a clinically significant advance over oral antipsychotics, improving adherence in chronic conditions. The ‘C’ suffix designation in the Canadian patent numbering system indicates a granted patent, and the number range suggests an application priority consistent with the mid-to-late 2000s development timeline of the INVEGA franchise.
INVEGA SUSTENNA is a commercially significant product in the global antipsychotic market, and CA2655335C forms part of the regulatory patent linkage that protects its Canadian exclusivity. The patent’s role in these NOC proceedings — and the court’s confirmation that a generic product monograph could induce infringement — suggests the claims address formulation specifics, dosing regimens, or administration protocols that are difficult for generics to design around without triggering the inducement threshold. This makes the patent strategically central to any Canadian market entry strategy for depot paliperidone products.
Should your team run an FTO against CA2655335C before entering the paliperidone palmitate market?
Any pharmaceutical company developing a generic, biosimilar, or novel long-acting injectable formulation of paliperidone palmitate for the Canadian market should treat CA2655335C as a mandatory FTO checkpoint. This case confirms the patent is actively enforced through the PM/NOC regime and that even the language of a product monograph can trigger infringement liability. R&D and regulatory teams working on depot antipsychotic formulations should engage IP counsel early — before label drafting — to assess claim exposure.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of CA2655335C, identify related family members across jurisdictions, and flag pending claims that may extend protection timelines. For product teams monitoring the INVEGA patent estate, Eureka’s claim monitoring alerts you to prosecution developments and new filings in the paliperidone palmitate space — helping you anticipate IP barriers before they become litigation events.
Run a freedom-to-operate analysis on CA2655335C to assess your product’s exposure
Run FTO in Eureka →Similar Canadian PM/NOC patent cases in the long-acting injectable antipsychotic space
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the Canadian pharmaceutical patent IP landscape
The Janssen v. Apotex appellate outcome reinforces key doctrines in Canadian PM/NOC patent litigation that every pharmaceutical IP team should monitor.
Product monographs are high-stakes IP documents in Canadian NOC proceedings
This case confirms that the drafting of a generic product monograph is not merely a regulatory exercise — it is a potential source of patent liability under the inducement test. Generic manufacturers should conduct patent analysis on label language before filing, and innovators should monitor competitor monographs as early infringement signals.
Appellate deference makes early Federal Court victories strategically durable
The palpable and overriding error standard means a well-constructed Federal Court record is extremely difficult to overturn on appeal in Canada. Innovator patentees who invest in thorough evidentiary foundations at first instance — particularly around influence and inducement — can expect appellate stability in their favour, as this case demonstrates.
Plaintiff v Defendant — key questions answered
The Federal Court of Appeal dismissed Apotex’s appeal on 12 January 2024, upholding the Federal Court’s declaratory judgment in favour of Janssen. The court found no palpable and overriding error in the lower court’s factual findings regarding CA2655335C and INVEGA SUSTENNA. Costs of $10,000 all-inclusive were awarded to Janssen.
CA2655335C is a granted Canadian patent held by Janssen that covers technology underlying INVEGA SUSTENNA, a once-monthly long-acting injectable formulation of paliperidone palmitate used to treat schizophrenia and schizoaffective disorder. It is listed on Canada’s patent register under the PM/NOC Regulations, enabling Janssen to seek declaratory relief against generic entrants.
Palpable and overriding error is the deferential standard Canadian appellate courts apply when reviewing a lower court’s findings of fact or mixed fact and law. An error is ‘palpable’ if it is obvious, and ‘overriding’ if it affected the outcome. Apotex was required to meet this high bar to disturb the Federal Court’s findings — it could not, and the appeal was dismissed.
Under Canadian patent law, a party who directs or procures another to infringe a patent can itself be liable for inducement. In PM/NOC proceedings, a generic’s product monograph — which guides prescribers and pharmacists — can constitute the required ‘influence’ if it directs use that falls within a patent’s claims. The Federal Court found this threshold was met, and the Court of Appeal declined to disturb that finding.
The dismissal of Apotex’s appeal maintains the declaratory judgment blocking or delaying its Notice of Compliance for a generic paliperidone palmitate product in Canada. While this ruling does not permanently foreclose all generic entry strategies, it confirms that Apotex’s proposed product monograph as filed would give rise to infringement of CA2655335C, requiring Apotex to redesign its approach or await patent expiry.
PatSnap Eureka searches patents and litigation data to answer instantly.